Board appointments at Algeta
This article was originally published in Scrip
Algeta (Norway), an oncology-focused company developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform, has elected Dr Judith Hemberger and Dr Kapil Dhingra non-executive directors. Dr Hemberger has more than 30 years' pharmaceutical and biotech industry experience, having most recently served as a venture partner at Nomura Phase4 Ventures and interim CEO of Zosano Pharma. Before that Dr Hemberger was co-founder, executive vice-president and chief operating officer of Pharmion. Dr Dhingra was formerly vice-president, head of the oncology disease biology leadership team, and head of oncology clinical development at Roche. Before that, he was clinical and senior clinical research physician at Lilly.
You may also be interested in...
US-based law firm Morgan Lewis has appointed Donna Lee Yesner and Stephen Ruscus as partners in its Food and Drug Administration and healthcare practice, based in Washington, DC. Ms Yesner is the co-chair of the healthcare contracting committee of the ABA Public Contracts Section, while Mr Ruscus focuses his practice on public healthcare, government contracts and litigation.
The San Diego, California-based biopharmaceutical company Optimer Pharmaceuticals has appointed Dr Nancy Ruiz senior vice-president of R&D, Cynthia Schwalm senior vice-president of international and Dr Kasia Petchel senior vice-president of pharmacovigilance. These newly created positions will strengthen the company's management team as it prepares for the potential launch of its lead product candidate, Dificid (fidaxomicin). Dr Ruiz joins from Merck Research Laboratories (formerly Schering-Plough Research Institute), where she served as vice-president of project and pipeline management for infectious diseases. Ms. Schwalm was previously president of Eisai Pharmaceuticals, the US commercial arm of Tokyo-based Eisai Co, while Dr Petchel was formerly vice-president of global head drug safety risk management at Roche.
Qforma, a provider of analytics and predictive modelling technologies for the health sciences industry, has elected Mark Spiers to its board of directors. Mr Spiers retired as president and CEO of Wolters Kluwer Pharma Solutions in April; he has also previously worked for Bristol-Myers Squibb, Pharmacia and MedPointe Pharmaceuticals.